CANBRIDGE-B News

CANbridge Pharma Terminates Lease in Massachusetts Amid US Downsizing Efforts

MT NewswiresFeb 25 04:29 ET

The "DeepSeek Moment" of medicine, has China’s Innovative Drugs also reached it?

Over the past four years, China's share of Global large-scale pharmaceutical Trade has surged from 5% to 30%. From research and development innovation to international mergers and acquisitions, Chinese Innovative Drugs companies are reshaping the Global pharmaceutical innovation landscape.

wallstreetcnFeb 7 20:59 ET

North Sea Kang Cheng - B [01228] is currently reported at HKD 0.148, with an increase of 19.36%.

As of 11:57, Beihai Kangcheng - B [01228] is priced at 0.148 Hong Kong dollars, an increase of 0.024 Hong Kong dollars or 19.36% compared to yesterday's closing price of 0.124 Hong Kong dollars, with a trading volume of 0.0222 million Hong Kong dollars. Today's highest price is 0.148 Hong Kong dollars, and the lowest price is 0.132 Hong Kong dollars. Based on yesterday's closing price, the 10-day average price is 0.12 Hong Kong dollars, the 50-day average price is 0.15 Hong Kong dollars, and the current PE is -0.13 times, with a 14-day strength index of 42.98.

Jinwu Financial NewsJan 21 22:57 ET

CANbridge Pharmaceuticals Inc.'s (HKG:1228) 25% Dip In Price Shows Sentiment Is Matching Revenues

Simply Wall StJan 14 17:07 ET

Highly resilient! Leading CRO companies have stabilized their fundamentals, but the shadow of the biosafety bill may still linger next year | Year-end review.

① In 2024, the USA Biodefense Act will disrupt CROs throughout the year and may continue next year; ② In the first three quarters of this year, over half of listed companies experienced revenue growth, and leading CROs demonstrated resilience; ③ Research on popular targets such as ADC, GLP-1, and bispecific antibodies will continue to be hot; ④ In 2025, the performance of leading CROs and small to medium enterprises may further diverge.

cls.cnDec 24, 2024 04:16 ET

Beihai Kangcheng announced that Mai Ruibei for the treatment of PFIC cholestatic pruritus has been approved for sale in Taiwan.

CANbridge PharmaceuticalsDec 18, 2024 04:57 ET

Beihai Kangcheng announced that Mireb will be applicable to ALGS patient populations in Taiwan for more than 2 months.

CANbridge PharmaceuticalsDec 18, 2024 04:34 ET

The U.S. bioterrorism law has undergone significant changes, the CRO concept has launched a major counterattack, and WuXi AppTec is excited!

Industry pessimistic expectations may improve.

Gelonghui FinanceDec 8, 2024 23:10 ET

How to break through the challenges in the development of innovative drugs? The industry suggests focusing on internationalization.

① The year 2024 will be the inaugural year of large-scale authorized trade, and going abroad has become an important direction for the development of local pharmaceutical companies; ② Chinese企业品牌, clinical trial capabilities, data presentation formats, and levels of international operation still need time and practical verification.

cls.cnDec 8, 2024 03:48 ET

CANbridge Pharmaceuticals' Auditor Steps Down; Successor Named

MT NewswiresDec 6, 2024 04:51 ET

CANbridge and Scriptr Global Announce Publication in the Journal Science Reporting the Discovery of the StitchR™ RNA Assembly Technology and its Application for the Treatment of Muscular Dystrophies

Moomoo NewsNov 15, 2024 02:37 ET

CANbridge Pharmaceuticals to Terminate Agreements to Downsize Operations in U.S.A

MT NewswiresOct 25, 2024 07:07 ET

CANbridge Pharmaceuticals Inc.'s (HKG:1228) Share Price Boosted 40% But Its Business Prospects Need A Lift Too

Simply Wall StOct 2, 2024 19:40 ET

BeiHai Kangcheng-B (01228): CAN103 for the treatment of Gaucher's Disease (GD) qualifies for priority review.

Beihai Kangcheng-B (01228) announced CAN103 (Vilapine β) for the treatment of Gaucher's disease (GD)...

Zhitong FinanceSep 30, 2024 08:15 ET

Express News | CANbridge Pharmaceuticals Inc - Grant of Priority Review Status of Can103 for Treatment of Gaucher Disease

ReutersSep 30, 2024 08:14 ET

Beihai Kangcheng-B (01228.HK) appoints Fangxin Li as a non-executive director.

Grondragon September 30th |Beihai Kangcheng-B(01228.HK) announced that Fangxin Li has been appointed as a non-executive director and a member of the board of directors' remuneration committee, effective from September 30, 2024. The board of directors has also received the resignation letter of Hu Zhengguo as a non-executive director and a member of the board of directors' remuneration committee, effective from the date of effectiveness.

Gelonghui FinanceSep 30, 2024 05:41 ET

Express News | CANbridge Pharmaceuticals Inc - James Qun Xue Will Assume Interim Duties and Responsibilities of CFO

ReutersSep 30, 2024 05:37 ET

Express News | CANbridge Pharmaceuticals Inc - Glenn Hassan Has Tendered His Resignation as Chief Financial Officer

ReutersSep 30, 2024 05:36 ET

CANbridge Pharmaceuticals’ CAN103 for Gaucher Disease has been granted Priority Review Status by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA).

CANbridgeSep 30, 2024 00:49 ET

Canbridge Pharmaceuticals Books Wider Attributable Loss in H1

MT NewswiresSep 27, 2024 05:39 ET